<DOC>
	<DOC>NCT00805480</DOC>
	<brief_summary>Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.</brief_summary>
	<brief_title>Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Diagnosis of plaque psoriasis for at least 6 months prior to screening. The patients must meet all of the following criterion: 1. Coverage of the body surface area (BSA) of 10% or more with plaques 2. A score of 3 or more on the IGA scale 3. A PASI score of at least 12 at baseline Have forms of psoriasis other than the required "plaque psoriasis" Women of childbearing potential Recent use of investigational drugs or treatment with other biological therapies (washout periods required) Previous treatment with this investigational drug Subjects with active or history of clinically significant cardiac, kidney or liver abnormalities; Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Plaque</keyword>
	<keyword>psoriasis</keyword>
	<keyword>inflammatory skin disease</keyword>
	<keyword>skin condition, thickening</keyword>
	<keyword>flaking</keyword>
	<keyword>scaly patches</keyword>
	<keyword>skin disease</keyword>
</DOC>